These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37139651)
1. Complexities of rifamycin use in persons with HIV infection. Nguyen NN; Winslow DL AIDS; 2023 Jun; 37(7):1161-1163. PubMed ID: 37139651 [No Abstract] [Full Text] [Related]
2. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Rabie H; Decloedt EH; Garcia-Prats AJ; Cotton MF; Frigati L; Lallemant M; Hesseling A; Schaaf HS Expert Opin Pharmacother; 2017 Apr; 18(6):589-598. PubMed ID: 28346018 [TBL] [Abstract][Full Text] [Related]
4. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients. Singh R; Marshall N; Smith CJ; Reynolds CJ; Breen RA; Bhagani S; Cropley I; Hopkins S; Swaden L; Johnson MA; Lipman MC AIDS; 2013 Jan; 27(3):481-4. PubMed ID: 23014518 [TBL] [Abstract][Full Text] [Related]
5. Recurrence of tuberculosis in HIV-1-infected adults treated after rifamycin-based treatment and highly active antiretroviral therapy. Hung CC; Hsiao CF J Acquir Immune Defic Syndr; 2003 Dec; 34(4):437-9. PubMed ID: 14615663 [No Abstract] [Full Text] [Related]
6. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259 [TBL] [Abstract][Full Text] [Related]
7. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Regazzi M; Carvalho AC; Villani P; Matteelli A Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631 [TBL] [Abstract][Full Text] [Related]
8. Why the treatment with Reprimun could be efficient for tuberculosis prevention in HIV infected individuals. Păunescu E Pneumoftiziologia; 1992; 41(1):45-6. PubMed ID: 1299399 [No Abstract] [Full Text] [Related]
10. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G J Infect; 2008 Jul; 57(1):78-81. PubMed ID: 18550175 [TBL] [Abstract][Full Text] [Related]
11. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB. TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607 [No Abstract] [Full Text] [Related]
12. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Huang JS; Jiang ZD; Garey KW; Lasco T; Dupont HL Antimicrob Agents Chemother; 2013 Jun; 57(6):2690-3. PubMed ID: 23545528 [TBL] [Abstract][Full Text] [Related]
13. Rifamycin SV versus triamcinolone in local treatment of rheumatoid synovitis. Marchesoni A; Sinigaglia L; Ranza R; Varenna M; Battafarano N; Tosi S Scand J Rheumatol; 1993; 22(4):194-8. PubMed ID: 8356413 [TBL] [Abstract][Full Text] [Related]